• ЗАРЕГИСТРИРОВАТЬСЯ

Аналитика фондового рынка, финансовые прогнозы

Получайте самые последние экономические новости от ForexMart, и вы своевременно будете узнавать о событиях на финансовых рынках, действия крупнейших центральных банков, финансовые показатели и будете в курсе другой актуальной информации, которая может повлиять на ход торговли.

Отказ от ответственности:  ForexMart не дает инвестиционных рекомендаций. Предоставляемый анализ не должен рассматриваться как обещание будущих результатов.

European stock exchanges are mainly growing on the risk sentiment of the markets


июля, 03 2023
watermark Economic news

The main stock indexes in Europe on Monday show mostly positive dynamics – the market is growing against the background of traders' propensity to risk, as well as against the background of rising commodity prices. 


In particular, the British FTSE 100 index rose 0.33% to 7,556.57 points, the French CAC 40 rose 0.14% to 7,410.22 points. At the same time, the German DAX fell by 0.12% to 16,128.05 points.


On the first trading day of July, investors are more risk-averse: Asian stock exchanges showed a significant increase of 2.1%, and American indices closed on Friday with an increase approaching 1.5%.


Additional support for the indices is provided by the growth in the cost of oil and copper, which increased by 0.7% and 0.6%, respectively. This has a positive impact on the shares of companies in the energy and mining sectors. As a result, BP shares rose by 3.1%, Eni – by 2%, Shell – by 2.2%, Glencore shares rose by 3.9%, Anglo American – by 5%, and Rio Tinto – by 3%.


At the same time, the further growth of the indices is hindered by weak internal macroeconomic statistics. Thus, the business activity index (PMI) in the industrial sector of the eurozone, according to the final estimate, fell to 43.4 points in June from 44.8 points in May, which was lower than the preliminary estimate of 43.6 points.


In addition, shares of the British company AstraZeneca fell by 5.8%, as the results of trials of the drug for patients with lung cancer did not meet the expectations of investors.


Top Top